Hemab Therapeutics, a clinical-stage biotechnology company, has raised $135 million in a Series B financing round for advancing prophylactic treatments for underserved bleeding and thrombotic disorders.

The company anticipates using the proceeds from the round to complete an ongoing phase 1/2 study of its bispecific antibody HMB-001 in Glanzmann Thrombasthenia apart from advancing its upcoming pipeline.

In late 2022, HMB-001, which also has potential for other bleeding disorders, entered phase 1/2 clinical evaluation, with initial data expected in the latter half of this year.

In addition, the investment will be used by Hemab Therapeutics to initiate pivotal studies, and start and conclude a phase 1/2 study of HMB-VWF in Von Willebrand Disease.

Benny Sorensen — Hemab Therapeutics CEO and President said: “Hemab is fundamentally reimagining the treatment paradigm for underserved bleeding and thrombotic disorders.

“This financing will allow us to progress our clinical programs for the first prophylactic treatments for Glanzmann Thrombasthenia and Von Willebrand Disease, delivering functional cures for patients in need.

“We’re grateful for this robust syndicate of investors who support our approach of leveraging validated advanced technologies and deep insights into the biology of clotting to overcome decades of scientific stagnation.”

The Series B financing round was led by Access Biotechnology, with existing investors Novo Holdings, HealthCap, and RA Capital Management.

New investors Deep Track Capital, Invus, Avoro Ventures, Maj Invest Equity, and Rock Springs Capital have also participated in the round.

Based in the US and Denmark, Hemab Therapeutics’ strategic guidance, Hemab 1-2-5 aims to develop five clinical assets by 2025. The assets will target patients with Factor VII Deficiency, Von Willebrand Disease, Bernard Soulier Syndrome, Congenital Antithrombin III Deficiency, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), and other disorders.

  Benny Sorensen, Denmark, Glanzmann Thrombasthenia, HealthCap, Hemab Therapeutics, HMB-001, HMB-VWF, Novo Holdings, RA Capital Management, Rock Springs Capital, USA